About Isolere Bio
Isolere Bio is a company based in Durham (United States) founded in 2017 by Joseph McMahon, Ashutosh Chilkoti, and Kelli Luginbuhl was acquired by Donaldson Company in February 2023. Isolere Bio has raised $7 million across 7 funding rounds from investors including Donaldson Company, HHS and NCBiotech. Isolere Bio offers products and services including IsoTag™ AAV and IsoTag™ LV. Isolere Bio operates in a competitive market with competitors including ExBiome, REV-MED, Zepteon, VIRAPUR and Norgen Biotek, among others.
- Headquarter Durham, United States
- Founders Joseph McMahon, Ashutosh Chilkoti, Kelli Luginbuhl
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Isolere Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7 M (USD)
in 7 rounds
-
Latest Funding Round
$255.56 K (USD), Grant
Feb 01, 2022
-
Investors
Donaldson Company
& 4 more
-
Employee Count
Not available
-
Acquired by
Donaldson Company
(Feb 21, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Isolere Bio
Isolere Bio offers a comprehensive portfolio of products and services, including IsoTag™ AAV and IsoTag™ LV.
Reagent for high-yield AAV purification without chromatography.
Reagent for efficient lentiviral vector purification processes.
People of Isolere Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Isolere Bio
Isolere Bio has successfully raised a total of $7M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $255.56 thousand completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Isolere Bio
Isolere Bio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Donaldson Company, HHS and NCBiotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Biotech startups are incubated and funded in North Carolina.
|
Locked | Locked | Locked | |
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked |
Investor details for Isolere Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Isolere Bio
Investment portfolio details for Isolere Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Isolere Bio
Detailed financials for Isolere Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Isolere Bio Comparisons
Peer comparison for Isolere Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Isolere Bio
Isolere Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ExBiome, REV-MED, Zepteon, VIRAPUR and Norgen Biotek, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develops innovative diagnostic technologies for cancer detection from blood samples.
|
|
| Locked | Locked | Locked |
Limited details on core medical activities are available.
|
|
| Locked | Locked | Locked |
Biomolecular separation tools for antibody potency evaluation are developed.
|
|
| Locked | Locked | Locked |
Provides viral reagents and assay services for scientific and medical research.
|
|
| Locked | Locked | Locked |
Offers kits and services for RNA, DNA extraction, purification, and genomics research.
|
Detailed competitors of Isolere Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Isolere Bio
Complete news archive for Isolere Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Isolere Bio
Isolere Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Isolere Bio is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Kelli Luginbuhl is the current CEO of Isolere Bio. They have also founded this company.
Isolere Bio is a funded company, having raised a total of $7M across 7 funding rounds to date.
Isolere Bio was founded in 2017 and is located in Durham, United States. A platform for the purification of biotherapeutics is offered, centered on tangential flow filtration (TFF) technology. Antibodies and adeno-associated viruses are developed and manufactured through this simplified TFF method within the biotechnology sector. Operations support the creation of new drugs and diagnostics by streamlining purification processes for biopharmaceutical applications.
Isolere Bio offers IsoTag™ AAV and IsoTag™ LV.
Isolere Bio has 5 investors. Key investors include Donaldson Company, HHS, NCBiotech, Northpond Ventures, and America’s Seed Fund.